Cha Bio&Diostech, Sorrento deal

Sorrento and Cha will form a JV to develop and commercialize chimeric antigen receptor (CAR)-modified cell therapies worldwide excluding China, Hong Kong, Macau and Taiwan. The JV will develop CAR therapies based on Cha’s activated killer cell (AKC) technology, including five Sorrento CAR therapies with which it will be combined, focusing on oncology and infectious disease. The AKC technology derives natural killer (NK) cells from a patient’s peripheral blood. ...